Immunotherapy in the Treatment of Prostate Cancer – Targeted Drug Approaches

Prostate cancer is one of the most common cancers in men. In recent years, there have been significant advances not only in surgery, radiation therapy, and hormone therapy but also in the field of immunotherapy. However, contrary to what many patients believe, immunotherapy is not a suitable treatment for every prostate cancer patient. Proper patient selection and evaluation of the tumor’s molecular characteristics play a decisive role in the success of treatment.

AsProf. Dr. Volkan İzol, when planning prostate cancer treatment, I evaluate not only the stage of the disease but also the tumor’s biological characteristics, genetic analyses, the patient’s overall health, and the latest scientific data. The goal is to provide each patient with the most effective and appropriate treatment.

What Is Immunotherapy?

Immunotherapy is the general term for treatment methods that enable the immune system to recognize and fight cancer cells.

Unlike conventional chemotherapy, which targets tumor cells directly, it helps the immune system recognize and destroy cancer more effectively.

In recent years, significant progress has been made in treating many types of cancer, such as lung cancer, melanoma, and kidney cancer.

Is Immunotherapy Effective for Prostate Cancer?

Prostate cancer is one of the cancers considered a “cold tumor” from the perspective of the immune system. For this reason, immunotherapy does not yield the same results in every patient.

However, quite promising results are being achieved in certain patient groups.

In particular;

  • Advanced (metastatic) prostate cancer
  • Castration-resistant prostate cancer (mCRPC)
  • Tumors with high microsatellite instability (MSI-H)
  • Patients with DNA repair mechanism defects

They may be among the groups that could benefit from immunotherapy.

Is Immunotherapy Suitable for Every Patient?

No.

Before deciding on immunotherapy, the patient must be evaluated in detail.

When necessary;

  • Genetic tests
  • MSI Analysis
  • dMMR assessment
  • BRCA1/BRCA2 Mutation Analysis
  • The tumor's molecular profile

can be examined.

These assessments play an important role in determining which patients may benefit from immunotherapy.

What Are the Side Effects of Immunotherapy?

Immunotherapy generally has different side effects than chemotherapy.

Possible side effects include:

  • Fatigue
  • Skin rash
  • Diarrhea
  • Thyroid Disorders
  • Elevated liver enzymes
  • Immune-mediated inflammation in the lungs, intestines, or other organs

is available.

When these side effects are detected early, they can often be successfully managed.

What Does the Future Hold for Us?

The field of immunotherapy for prostate cancer is advancing rapidly.

Today, intensive research is being conducted, particularly in the following areas:

  • Personalized cancer vaccines
  • Next-generation immune checkpoint inhibitors
  • CAR-T cell therapies
  • Bispecific antibodies
  • The combined use of PSMA-targeted therapies and immunotherapy

With the advancement of molecular diagnostic methods in the coming years, it is expected that more patients will benefit from these treatments.

Conclusion

Immunotherapy is a promising treatment option for prostate cancer, but it requires careful patient selection.Although it is not currently used for every prostate cancer patient, it can provide significant benefits, particularly for patients with advanced-stage disease and specific molecular characteristics. AsProf. Dr. Volkan İzol, my goal is to determine the most appropriate treatment approach by evaluating current scientific data, international guidelines, and all patient-specific characteristics together during treatment planning.